Meridian Bioscience Inc (VIVO) 21.82 $VIVO
Meridian Bioscience Slips to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 1:50PM CDT
Meridian's adjusted earnings per share decreased 10% year over year to 18 cents during first-quarter fiscal 2014.
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Edwards' Intuity Elite Cleared in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:10PM CDT
Edwards Lifesciences has received CE Mark approval for its Intuity Elite valve system.
New Jobs at Baxter's Malta Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:03PM CDT
BAX is seen making efforts to meet its current and future business needs by investing in its manufacturing infrastructure and employee capabilities.
Boston Scientific Posts Encouraging CRT-TAVR Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 2:00PM CDT
Boston Scientific's shares gained 0.8% in the trading session that followed the release of the study results.
Medtronic Up on Positive CoreValve Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 5:40PM CDT
Shares of Medtronic rallied nearly 2% since the company announced favorable data on CoreValve at the American College of Cardiology.
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
The Market and Potential for Molecular Point of Care Diagnostics Report Provides Market Estimates up to 2018
M2 - Mon Mar 31, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb6tbz/the_market_and) has announced the addition of the "The Market and Potential for Molecular Point of Care Diagnostics" report to their offering. The molecular diagnostic market and the point-of-care (POC) testing markets are two of the fastest growing segments of the overall IVD market. Historically, these have been completely different market segments. Not anymore. There has been a growing interest in developing molecular diagnostic platforms that can be used in POC settings. Indeed, as this new market research report details, the emerging area of rapid molecular POC testing has attracted over $650 million in investments and financings over the past five years (2009 to 2013). The Market and Potential for Molecular Point of Care Diagnostics, offers a quantitative assessment of the molecular diagnostic market, and of the point-of-care (POC) testing market, and then looks at the emerging field of molecular diagnostic POC testing. Many companies are developing molecular diagnostic platforms and assays that are designed to for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The initial market focus for most of these companies is on infectious disease testing, where rapid test results generate important actionable information that physicians can use to make treatment decisions. Over 75 companies involved in this market are profiled in this report. As expected with any group of start-up companies, many are struggling or are surviving on limited financial resources. However, some new companies that are focusing on molecular diagnostic POC testing have received significant investments. Some of the Companies Mentioned: - Abacus Diagnostica Oy - bioMerieux sa - Canon U.S. Life Sciences - DiaSorin S.p.A. - Espira, Inc. - Focus Diagnostics, Inc. - GenePOC Inc. - Instrumentation Laboratory - Lumora Ltd - Meridian Bioscience, Inc. - NetBio, Inc. - OptiGene Ltd. - PositiveID Corporation - QIAGEN N.V - Spartan Bioscience Inc. - Veredus Laboratories - Wave 80 Biosciences - Xagenic Inc. For more information visit http://www.researchandmarkets.com/research/gb...market_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
Balanced View on Hanger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:50PM CDT
We are impressed with the Hanger's higher revenues and EPS guidance riding on improvements in Patient Care segment.
Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene(R) Pertussis
Business Wire - Thu Mar 27, 1:05PM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Bordetella pertussis (B. pertussis), its fifth assay on the illumigene platform. This innovative test is the first FDA-cleared molecular stand-alone assay for B. pertussis providing a solution to the unmet need of today's healthcare market.
Baxter Downgraded to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 11:10AM CDT
Baxter's operating margin dropped 280 basis points (bps) year over year to 21% in the quarter.
Neogen Meets Q3 Earnings Ests, Beats Rev - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 9:50AM CDT
Neogen reported flat year over year adjusted earnings per share of 18 cents for the third quarter of fiscal 2014, in line with the Zacks Consensus Estimate.
St. Jude Medical's Prodigy Neurostimulator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 3:00PM CDT
St. Jude Medical's Prodigy Chronic Pain System is based on neurostimulation therapy in addition to Burst Technology.
Trinity Biotech (TRIB) Falls: Stock Goes Down 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 9:00AM CDT
Trinity Biotech saw a big move last session, this breaks the recent trend of the company, as the stock is now trading below the volatile price range
Shares of VIVO Down 13.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 12, 9:59AM CDT
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on January 16th, 2014 at $25.37. In approximately 2 months, Meridian Bioscience has returned 13.76% as of today's recent price of $21.88.
Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018 Out Now
M2 - Fri Mar 07, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/4hmks6/global_isothermal) has announced the addition of the "Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018" report to their offering. The analysts forecast the Global Isothermal Nucleic Acid Amplification Technologies market will grow at a CAGR of 17.49 percent over the period 2013-2018. One of the key factors contributing to this market growth is the technological advances being made in this domain. The Global Isothermal Nucleic Acid Amplification Technologies market has also been witnessing an increase in the miniaturization of nucleic acid-based diagnostics. However, the tough competition from PCR-based diagnostics could pose a challenge to the growth of this market. The key vendors dominating this space are Becton, Dickson and Co., bioMerieux S.A., Hologic Inc., Novartis International AG., and Quidel Corp. The other vendors mentioned in the report are Alere Inc., Axxin Pvt Ltd., Eiken Chemical Co. Ltd., Great Basin Corp., Lucigen Corp., Meridian Bioscience Inc., New England Biolabs Inc., and Optigene Ltd. Commenting on the report, an analyst from the team said: The Molecular Diagnostics industry is experiencing a rapid shift toward an increase in the process automation and integration of sample analysis in single miniaturized devices. Miniaturization offers scope for reduced sample volume, enabling the end-user to automate and analyze the sample. Among all the diagnostic methods, nucleic acid testing remains the method with the most potential for conducting analysis in miniaturized devices. Although PCR is one of the standard techniques for conducting amplification reaction, the method is quite complex due to the need for repeated thermo cycling and cooling, and it consumes more energy in the process. As an alternative to PCR, isothermal nucleic amplification circumvents the need for repeated denaturation and cooling as the amplification reaction occurs under isothermal conditions. This greatly aids in the design of microfluidic chips for conducting molecular diagnostics. Most of these microfluidic devices adopting isothermal nucleic acid amplification methods are in the R&D phase. It is expected that the increase in miniaturization of nucleic acid-based diagnostics will boost the growth of the market. For more information visit http://www.researchandmarkets.com/research/4h...isothermal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Meridian Bioscience Slips to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 1:50PM CDT
Meridian's adjusted earnings per share decreased 10% year over year to 18 cents during first-quarter fiscal 2014.
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Edwards' Intuity Elite Cleared in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:10PM CDT
Edwards Lifesciences has received CE Mark approval for its Intuity Elite valve system.
New Jobs at Baxter's Malta Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:03PM CDT
BAX is seen making efforts to meet its current and future business needs by investing in its manufacturing infrastructure and employee capabilities.
Boston Scientific Posts Encouraging CRT-TAVR Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 2:00PM CDT
Boston Scientific's shares gained 0.8% in the trading session that followed the release of the study results.
Medtronic Up on Positive CoreValve Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 5:40PM CDT
Shares of Medtronic rallied nearly 2% since the company announced favorable data on CoreValve at the American College of Cardiology.
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
The Market and Potential for Molecular Point of Care Diagnostics Report Provides Market Estimates up to 2018
M2 - Mon Mar 31, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb6tbz/the_market_and) has announced the addition of the "The Market and Potential for Molecular Point of Care Diagnostics" report to their offering. The molecular diagnostic market and the point-of-care (POC) testing markets are two of the fastest growing segments of the overall IVD market. Historically, these have been completely different market segments. Not anymore. There has been a growing interest in developing molecular diagnostic platforms that can be used in POC settings. Indeed, as this new market research report details, the emerging area of rapid molecular POC testing has attracted over $650 million in investments and financings over the past five years (2009 to 2013). The Market and Potential for Molecular Point of Care Diagnostics, offers a quantitative assessment of the molecular diagnostic market, and of the point-of-care (POC) testing market, and then looks at the emerging field of molecular diagnostic POC testing. Many companies are developing molecular diagnostic platforms and assays that are designed to for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The initial market focus for most of these companies is on infectious disease testing, where rapid test results generate important actionable information that physicians can use to make treatment decisions. Over 75 companies involved in this market are profiled in this report. As expected with any group of start-up companies, many are struggling or are surviving on limited financial resources. However, some new companies that are focusing on molecular diagnostic POC testing have received significant investments. Some of the Companies Mentioned: - Abacus Diagnostica Oy - bioMerieux sa - Canon U.S. Life Sciences - DiaSorin S.p.A. - Espira, Inc. - Focus Diagnostics, Inc. - GenePOC Inc. - Instrumentation Laboratory - Lumora Ltd - Meridian Bioscience, Inc. - NetBio, Inc. - OptiGene Ltd. - PositiveID Corporation - QIAGEN N.V - Spartan Bioscience Inc. - Veredus Laboratories - Wave 80 Biosciences - Xagenic Inc. For more information visit http://www.researchandmarkets.com/research/gb...market_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
Balanced View on Hanger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:50PM CDT
We are impressed with the Hanger's higher revenues and EPS guidance riding on improvements in Patient Care segment.
Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene(R) Pertussis
Business Wire - Thu Mar 27, 1:05PM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Bordetella pertussis (B. pertussis), its fifth assay on the illumigene platform. This innovative test is the first FDA-cleared molecular stand-alone assay for B. pertussis providing a solution to the unmet need of today's healthcare market.
Baxter Downgraded to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 11:10AM CDT
Baxter's operating margin dropped 280 basis points (bps) year over year to 21% in the quarter.
Neogen Meets Q3 Earnings Ests, Beats Rev - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 9:50AM CDT
Neogen reported flat year over year adjusted earnings per share of 18 cents for the third quarter of fiscal 2014, in line with the Zacks Consensus Estimate.
St. Jude Medical's Prodigy Neurostimulator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 3:00PM CDT
St. Jude Medical's Prodigy Chronic Pain System is based on neurostimulation therapy in addition to Burst Technology.
Trinity Biotech (TRIB) Falls: Stock Goes Down 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 9:00AM CDT
Trinity Biotech saw a big move last session, this breaks the recent trend of the company, as the stock is now trading below the volatile price range
Shares of VIVO Down 13.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 12, 9:59AM CDT
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on January 16th, 2014 at $25.37. In approximately 2 months, Meridian Bioscience has returned 13.76% as of today's recent price of $21.88.
Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018 Out Now
M2 - Fri Mar 07, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/4hmks6/global_isothermal) has announced the addition of the "Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018" report to their offering. The analysts forecast the Global Isothermal Nucleic Acid Amplification Technologies market will grow at a CAGR of 17.49 percent over the period 2013-2018. One of the key factors contributing to this market growth is the technological advances being made in this domain. The Global Isothermal Nucleic Acid Amplification Technologies market has also been witnessing an increase in the miniaturization of nucleic acid-based diagnostics. However, the tough competition from PCR-based diagnostics could pose a challenge to the growth of this market. The key vendors dominating this space are Becton, Dickson and Co., bioMerieux S.A., Hologic Inc., Novartis International AG., and Quidel Corp. The other vendors mentioned in the report are Alere Inc., Axxin Pvt Ltd., Eiken Chemical Co. Ltd., Great Basin Corp., Lucigen Corp., Meridian Bioscience Inc., New England Biolabs Inc., and Optigene Ltd. Commenting on the report, an analyst from the team said: The Molecular Diagnostics industry is experiencing a rapid shift toward an increase in the process automation and integration of sample analysis in single miniaturized devices. Miniaturization offers scope for reduced sample volume, enabling the end-user to automate and analyze the sample. Among all the diagnostic methods, nucleic acid testing remains the method with the most potential for conducting analysis in miniaturized devices. Although PCR is one of the standard techniques for conducting amplification reaction, the method is quite complex due to the need for repeated thermo cycling and cooling, and it consumes more energy in the process. As an alternative to PCR, isothermal nucleic amplification circumvents the need for repeated denaturation and cooling as the amplification reaction occurs under isothermal conditions. This greatly aids in the design of microfluidic chips for conducting molecular diagnostics. Most of these microfluidic devices adopting isothermal nucleic acid amplification methods are in the R&D phase. It is expected that the increase in miniaturization of nucleic acid-based diagnostics will boost the growth of the market. For more information visit http://www.researchandmarkets.com/research/4h...isothermal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
